Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen α‐chain variant in an English family
Open Access
- 1 May 2000
- journal article
- case report
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 93 (5) , 269-275
- https://doi.org/10.1093/qjmed/93.5.269
Abstract
A 53‐year‐old English woman who had been thought to have systemic monoclonal immunoglobulin light chain (AL) amyloidosis was investigated further because of her unusually long 17‐year history and a suggestion of renal disease in the family. She was found to have the Glu526Val fibrinogen α‐chain variant that causes autosomal dominant hereditary systemic amyloidosis. This has not previously been described in a British family. The mutant gene was associated with the same haplotype as in all other reported cases, suggesting a common founder. The patient had already received a renal transplant, but the graft failed within 6 years due to amyloid deposition. Progressive hepatic amyloidosis eventually caused liver failure, although the function of other organs was well preserved. She therefore received hepatic and renal transplants to replace the failed organs and the hepatic source of the amyloidogenic variant fibrinogen. Three years later she is completely well and has no amyloid deposits identifiable by serum amyloid P component scintigraphy. This is the first detailed report of hepatic transplantation for liver failure caused by amyloidosis of any type. The substantial follow‐up suggests that fibrinogen α‐chain amyloidosis is one of the inherited metabolic diseases that can be cured by liver transplantation. The mutation underlying Glu526Val fibrinogen α‐chain amyloidosis is incompletely penetrant and has a variable phenotype that can clinically mimic AL amyloidosis. Hereditary fibrinogen amyloidosis may be more prevalent than previously suspected and, since AL amyloid is sometimes a diagnosis of exclusion, genotyping for other amyloidogenic proteins is mandatory in all cases in which the amyloid fibrils cannot be positively identified as AL.Keywords
This publication has 29 references indexed in Scilit:
- The New Apolipoprotein A-I Variant Leu174 → Ser Causes Hereditary Cardiac Amyloidosis, and the Amyloid Fibrils Are Constituted by the 93-Residue N-Terminal PolypeptideThe American Journal of Pathology, 1999
- A Novel Apolipoprotein A-1 Variant, Arg173Pro, Associated with Cardiac and Cutaneous AmyloidosisBiochemical and Biophysical Research Communications, 1999
- Hereditary Amyloid Cardiomyopathy Caused by a Variant Apolipoprotein A1The American Journal of Pathology, 1999
- The molecular basis of renal amyloidosis in Irish-American and Polish-Canadian kindredsQJM: An International Journal of Medicine, 1996
- Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.Journal of Clinical Investigation, 1996
- Hereditary renal amyloidosis with a novel variant fibrinogen.Journal of Clinical Investigation, 1994
- Human lysozyme gene mutations cause hereditary systemic amyloidosisNature, 1993
- Hereditary renal amyloidosis associated with a mutant fibrinogen α–chainNature Genetics, 1993
- Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis.Proceedings of the National Academy of Sciences, 1992
- New USA Family has Apolipoprotein AI (ARG26) VariantPublished by Springer Nature ,1991